Liraglutide Research Guide

Full name: Liraglutide (GLP-1 Receptor Agonist / Saxenda)

The first GLP-1 receptor agonist approved for chronic weight management (as Saxenda at 3.0mg). A 97% homolog of native GLP-1 with fatty acid modification for once-daily dosing.

How Liraglutide Works

Binds and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through hypothalamic signaling.

Dosing Protocol

• Typical dose: 0.6-3.0 mg
• Frequency: Once daily
• Duration: Ongoing
• Route: Subcutaneous

Reported Benefits

• Proven weight loss (5-10%)
• Long safety track record
• Cardiovascular benefit
• Improved glycemic control
• Reduced food intake

Potential Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Headache
• Pancreatitis (rare)

Research Citations

1. SCALE Obesity: Liraglutide 3.0mg for weight management (2015) - Liraglutide 3.0mg produced 8.0% weight loss vs 2.6% placebo with 63% achieving 5%+ loss at 56 weeks.
2. LEADER cardiovascular outcomes trial (2016) - Liraglutide reduced major cardiovascular events by 13% and cardiovascular death by 22% in T2DM patients.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Liraglutide profile with 3D molecule viewer →